Company Overview - Akari Therapeutics is a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment [4] - The company utilizes an innovative ADC discovery platform to create novel bi-functional ADC candidates, optimizing them for various cancer applications [4] Lead Product Candidate - Akari's lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells and employs a proprietary linker to deliver its novel PH1 payload directly into tumors [4] - PH1 is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while minimizing off-target toxicity [4] - Preclinical studies indicate that AKTX-101 has superior activity, prolonged survival, and better tolerability compared to current ADCs [4] Synergistic Potential - AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival in preclinical models [4] - The company is generating validating data on its novel payloads to advance its pipeline [4] Investor Engagement - Akari Therapeutics participated in the Virtual Investor "Top 5 for '25" On-Demand Conference, where the CEO presented key reasons for investment consideration in 2025 [2][3]
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference